Tadekinig alfa - Merck Serono

Drug Profile

Tadekinig alfa - Merck Serono

Alternative Names: IL-18 binding protein - Merck Serono; IL-18bp - Merck Serono; Interleukin-18 binding protein - Merck Serono; r-IL-18 bp - Merck Serono; Tadekinig-α - Merck Serono

Latest Information Update: 08 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yeda Research and Development Company Ltd
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Interleukin 18 inhibitors; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 27 Jan 2005 Discontinued - Phase-I for Crohn's disease in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top